Table 5.
The levels of plasma IgG against peptide antigens derived from specific target molecules in subgroups of NSCLC.
| IgG | Group a | Patient（n） | Control（n） | Z b | P c |
|---|---|---|---|---|---|
| POU5F1 | I | 0.735 ± 0.640 (121) | 0.806 ± 0.593 (200) | −2.463 | 0.014 |
| II | 0.678 ± 0.369 (41) | 0.806 ± 0.593 (200) | −1.340 | 0.180 | |
| III | 0.778 ± 0.503 (49) | 0.806 ± 0.593 (200) | −0.392 | 0.695 | |
| TNF‐α | I | 1.031 ± 0.338 (121) | 1.079 ± 0.327 (200) | −1.928 | 0.054 |
| II | 1.137 ± 0.354 (41) | 1.079 ± 0.327 (200) | −0.738 | 0.461 | |
| III | 1.142 ± 0.330 (49) | 1.079 ± 0.327 (200) | −0.876 | 0.381 | |
| CD25‐MUC1‐VEGFR1 | I | 0.347 ± 0.107 (121) | 0.537 ± 0.118 (200) | −11.504 | ＜0.001 |
| II | 0.376 ± 0.087 (41) | 0.537 ± 0.118 (200) | −7.279 | ＜0.001 | |
| III | 0.384 ± 0.093 (49) | 0.537 ± 0.118 (200) | −7.507 | ＜0.001 |
Plasma IgG levels were expressed as mean ± SD in SBI.
a
Group I for stages 1and 2A, group II for stage 2B, and group III for stages 3 and 4.
b
Mann–Whitney U test (two‐tailed).
c
P < 0.017 was considered statistically significant based on the Bonferroni correction.